Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer. Michiels, S.; Pugliano, L.; Marguet, S.; Grun, D.; Barinoff, J.; Cameron, D.; Cobleigh, M.; Di Leo, A.; Johnston, S.; Gasparini, G.; Kaufman, B.; Marty, M.; Nekljudova, V.; Paluch-Shimon, S.; Penault-Llorca, F.; Slamon, D.; Vogel, C.; von Minckwitz, G.; Buyse, M.; Piccart, M.. Ann Oncol. 2016; 1029-34: p.1029-34. doi:10.1093/annonc/mdw132 10.1093/annonc/mdw132. Epub 2016 Mar 8.Article
Oncostat